Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...